Abstract: Objective:To evaluate the efficacy and safety of erlotinib, in combination with chemotherapy, for advanced pancreatic cancer.Methods:Erlotinib was taken orally, 100 ~150 mg/d daily, combined with either gemcitabine monothera-py, gemcitabine/capcitabine, gemcitabine/cisplatin, or oxaliplatin/leucovorin/ 5FU (FOLFOX). Tumor response was evaluat-ed by RECIST criteria, and adverse events were evaluated by NCI-CTC AE v3.0. Results: 18cases of advanced pancreatic cancer were retrospectively analyzed. Tumor response was evaluated in 16 cases, with an objective response rate of 12.5% and disease control rate of68.7%. mTTF was2.90m, mOS was 5.47m, and1-year survival rate was 28.6%. mOS was related to severity of skin rash. OS in patients with rash grade 2/3 and patients with rash grade 0/1 were10.93m and 3.90 m, respectively (P=0.011 ). Main adverse events included rash ( 77.8% ), neutropenia (66.7% ), thrombocytopenia (33.3%), nausea/vomiting (50.0%), and fatigue (33.3%). Most were minor and well tolerated, less than grade 2. Conclusion: Erlotinib, in combination with chemotherapy, is effective in treating advanced pancreatic cancer and well tolerated by the pa-tient. It is worthy of further study on a large scale.